Is AURA or UNCY more profitable?

Aura Biosciences' return on equity of -78.12% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Unicycive Therapeutics N/A -134.69% -84.51%

Does the media prefer AURA or UNCY?

In the previous week, Aura Biosciences and Aura Biosciences both had 2 articles in the media. Unicycive Therapeutics' average media sentiment score of 0.94 beat Aura Biosciences' score of 0.19 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOA or UNCY?

In the previous week, BioAge Labs had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for BioAge Labs and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat BioAge Labs' score of 0.72 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALLO or UNCY more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Unicycive Therapeutics N/A -134.69% -84.51%

Does the media prefer ALLO or UNCY?

In the previous week, Allogene Therapeutics had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat Allogene Therapeutics' score of 0.53 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLDB or UNCY more profitable?

Solid Biosciences' return on equity of -73.42% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Unicycive Therapeutics N/A -134.69% -84.51%

Does the media refer more to SLDB or UNCY?

In the previous week, Solid Biosciences had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat Solid Biosciences' score of 0.72 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Unicycive Therapeutics (UNCY) Competitors

$7.20 -0.03 (-0.41%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$7.16 -0.04 (-0.57%)

As of 06/3/2026 07:55 PM Eastern

Compare

UNCY vs. AURA, BIOA, PHAT, ALLO, and SLDB

Should you buy Unicycive Therapeutics stock or one of its competitors? MarketBeat compares Unicycive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Unicycive Therapeutics include Aura Biosciences (AURA), BioAge Labs (BIOA), Phathom Pharmaceuticals (PHAT), Allogene Therapeutics (ALLO), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Unicycive Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Unicycive Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Unicycive Therapeutics	$680K	282.71	-$26.56M	-$2.21	N/A

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 197.97%. Unicycive Therapeutics has a consensus price target of $24.75, suggesting a potential upside of 243.75%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aura Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

In the previous week, Aura Biosciences and Aura Biosciences both had 2 articles in the media. Unicycive Therapeutics' average media sentiment score of 0.94 beat Aura Biosciences' score of 0.19 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aura Biosciences' return on equity of -78.12% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Summary

Unicycive Therapeutics beats Aura Biosciences on 9 of the 13 factors compared between the two stocks.

How does Unicycive Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by company insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BioAge Labs had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for BioAge Labs and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat BioAge Labs' score of 0.72 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

BioAge Labs currently has a consensus target price of $43.50, suggesting a potential upside of 171.20%. Unicycive Therapeutics has a consensus target price of $24.75, suggesting a potential upside of 243.75%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Unicycive Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Unicycive Therapeutics has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	79.31	-$80.61M	-$2.40	N/A
Unicycive Therapeutics	$680K	282.71	-$26.56M	-$2.21	N/A

Summary

Unicycive Therapeutics beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Phathom Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 147.77%. Unicycive Therapeutics has a consensus price target of $24.75, indicating a potential upside of 243.75%. Given Unicycive Therapeutics' higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Unicycive Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Unicycive Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.60	-$221.25M	-$2.12	N/A
Unicycive Therapeutics	$680K	282.71	-$26.56M	-$2.21	N/A

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.87 beat Unicycive Therapeutics' score of 0.94 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Unicycive Therapeutics	Positive

Phathom Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Unicycive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Allogene Therapeutics presently has a consensus price target of $8.52, indicating a potential upside of 326.11%. Unicycive Therapeutics has a consensus price target of $24.75, indicating a potential upside of 243.75%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Allogene Therapeutics had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat Allogene Therapeutics' score of 0.53 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics has higher revenue and earnings than Allogene Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,515.00	-$190.89M	-$0.77	N/A
Unicycive Therapeutics	$680K	282.71	-$26.56M	-$2.21	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Allogene Therapeutics' return on equity of -56.45% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Summary

Allogene Therapeutics beats Unicycive Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, Solid Biosciences had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.94 beat Solid Biosciences' score of 0.72 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Unicycive Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Unicycive Therapeutics	$680K	282.71	-$26.56M	-$2.21	N/A

Solid Biosciences' return on equity of -73.42% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Solid Biosciences currently has a consensus target price of $16.82, suggesting a potential upside of 145.52%. Unicycive Therapeutics has a consensus target price of $24.75, suggesting a potential upside of 243.75%. Given Unicycive Therapeutics' higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Solid Biosciences beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$193.04M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-3.26	17.69	22.17	24.18
Price / Sales	282.71	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	5.11	3.85	9.84	6.72
Net Income	-$26.56M	$75.85M	$3.57B	$337.19M
7 Day Performance	2.56%	-3.99%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-7.10%	19.65%	26.49%	33.10%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	3.9133 of 5 stars	$7.20 -0.4%	$24.75 +243.8%	-5.6%	$193.04M	$680K	N/A	9	Analyst Forecast
AURA Aura Biosciences	2.8937 of 5 stars	$6.97 -6.7%	$20.50 +194.2%	+8.7%	$772.30M	N/A	N/A	50
BIOA BioAge Labs	3.5531 of 5 stars	$16.30 -5.8%	$43.50 +167.0%	N/A	$768.59M	$10.32M	N/A	N/A
PHAT Phathom Pharmaceuticals	2.6949 of 5 stars	$9.37 -2.3%	$25.00 +166.7%	+103.8%	$764.86M	$204.89M	N/A	110
ALLO Allogene Therapeutics	2.5785 of 5 stars	$2.11 -3.0%	$8.52 +304.9%	+48.1%	$748.99M	N/A	N/A	310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. AURA, BIOA, PHAT, ALLO, and SLDB

How does Unicycive Therapeutics compare to Aura Biosciences?

Summary

How does Unicycive Therapeutics compare to BioAge Labs?

Summary

How does Unicycive Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Unicycive Therapeutics compare to Allogene Therapeutics?

Summary

How does Unicycive Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. AURA, BIOA, PHAT, ALLO, and SLDB

How does Unicycive Therapeutics compare to Aura Biosciences?

Which has stronger valuation & earnings, AURA or UNCY?

Do insiders & institutionals have more ownership in AURA or UNCY?

Do analysts rate AURA or UNCY?

Which has more risk & volatility, AURA or UNCY?

Does the media prefer AURA or UNCY?

Is AURA or UNCY more profitable?

Summary

How does Unicycive Therapeutics compare to BioAge Labs?

Do institutionals and insiders have more ownership in BIOA or UNCY?

Does the media prefer BIOA or UNCY?

Which has more volatility & risk, BIOA or UNCY?

Do analysts rate BIOA or UNCY?

Is BIOA or UNCY more profitable?

Which has better earnings and valuation, BIOA or UNCY?

Summary

How does Unicycive Therapeutics compare to Phathom Pharmaceuticals?

Do analysts prefer PHAT or UNCY?

Is PHAT or UNCY more profitable?

Which has higher earnings & valuation, PHAT or UNCY?

Does the media prefer PHAT or UNCY?

Which has more risk & volatility, PHAT or UNCY?

Do institutionals & insiders have more ownership in PHAT or UNCY?

Summary

How does Unicycive Therapeutics compare to Allogene Therapeutics?

Which has more risk and volatility, ALLO or UNCY?

Do analysts rate ALLO or UNCY?

Does the media prefer ALLO or UNCY?

Which has stronger earnings & valuation, ALLO or UNCY?

Do insiders and institutionals have more ownership in ALLO or UNCY?

Is ALLO or UNCY more profitable?

Summary

How does Unicycive Therapeutics compare to Solid Biosciences?

Does the media refer more to SLDB or UNCY?

Which has more risk & volatility, SLDB or UNCY?

Do institutionals & insiders hold more shares of SLDB or UNCY?

Which has higher earnings and valuation, SLDB or UNCY?

Is SLDB or UNCY more profitable?

Do analysts prefer SLDB or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools